Novel Nucleic Acid Sequencing Technology Development (R43/R44 Clinical Trial Not Allowed)

archived

This Funding Opportunity Announcement (FOA) solicits R43/R44 grant applications from small businesses to develop novel technologies that will enable no less than one order of magnitude improvement in DNA sequencing, and practical methods for direct RNA sequencing. Advances in genomics and more broadly in biomedical research have been greatly facilitated by significant and sustained DNA sequencing throughput increases and cost decreases. The goal now is to improve the quality and efficiency of DNA sequencing and enable direct RNA sequencing (e.g., longer read lengths, faster turn-around time, greater accuracy, and higher-throughput etc.) at reasonable costs with the anticipation that significant advances in any of these and related areas would make significant contributions to the mission of NHGRI and the field of genomics, including to many of NHGRIs other technology development goals.

High